South Africa weighs local production of HIV prevention jab lenacapavir

South Africa is considering domestic manufacturing of lenacapavir, a six-monthly HIV prevention injection, balancing immediate affordable access against long-term regional production capacity. The debate centers on cost and speed of local production versus importing the drug. This matters for HIV prevention access in high-burden regions and for Africa's pharmaceutical sovereignty.